J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn

Another Next-Generation Approach to CAR-Ts

Investment from Janssen helps to validate the platform developed by the San Diego-based company.

Johnson_and_Johnson

More from Business

More from Scrip